-
Prague’s Concert for the Future Kicks Off on Wenceslas Square
-
Apple Watch Live Rewind and Siri Recap: Privacy Concerns and Social Awkwardness
-
Prince William and Princess of Wales to Announce Earthshot Prize Winners in Mumbai
-
Rob Green Transforms Nottingham Central Library into Intimate Stage for Undercover Tour Finale
-
Indonesia Forest Fires: Health Crisis, Diplomatic Strains and the Search for Solutions
-
Proposed Fiscal Anchor Threatens South Africa’s Constitutional Rights Amid Health Crisis
-
BYD Dolphin G Leasing Deal: Plug-in Hybrid Supermini Available from £174 a Month
-
Freezz Italia Awarded ESA Contract for IRIS(2) Low-LEO Pre-Operational and De-Risk Activities
-
JUEL Group Expands from Real Estate to Hospitality with Hyatt Centric Malta Opening
-
Three Inaugural CombatX Champions Crowned at BRAVE CF Road to BRAVE Event in Hungary
-
French Economy Shrinks 0.1% as Consumer Confidence Slumps
-
China's Factory Activity Contracts as Export Orders Weaken
-
Wall Street Ends Turbulent Week Higher Despite Inflation and AI Jitters
Trump 'considering' push to reclassify marijuana as less dangerous
US President Donald Trump on Monday said his administration could push to loosen federal restrictions on marijuana, reclassifying it as a less dangerous drug.
"We are considering that," Trump told reporters after he was queried whether an executive order on the issue was being discussed.
"A lot of people want to see it, the reclassification, because it leads to tremendous amounts of research that can't be done unless you reclassify, so we are looking at that very strongly."
At the federal level, marijuana is currently classified as a Schedule I substance, in the same league as drugs like heroin and LSD. The government considers these drugs to have high abuse potential without accepted use for medical treatment.
But dozens of US states already have legal medical marijuana programs, and many also have approved its recreational use.
According to a recent Washington Post report, Trump is aiming to push for a reclassification to Schedule III -- substances that are considered to have medical value and less potential for abuse.
That class includes ketamine and anabolic steroids.
Rescheduling is not legalization or decriminalization -- but easing federal restrictions could have ripple effects, including lowering barriers to pursue research, as authorizing clinical studies on Schedule I substances can require many layers of approval.
It could also have major tax implications for companies that legally grow and sell cannabis.
The US president cannot unilaterally reclassify a drug. The Post reported that Trump is expected to sign an executive order directing federal agencies to pursue reclassification.
Joe Biden's administration had previously pursued reclassification, but efforts stalled and were not completed before Trump took office in early 2025.
The US has a patchwork of state-level regulations regarding the commercial distribution, recreational possession and personal cultivation of cannabis.
In small amounts it is already legal for recreational use in 24 US states as well as Washington DC.
K.Thomson--BTB